Simulations Plus, Inc. (NASDAQ:SLP) Given $25.00 Consensus Target Price by Analysts
Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been assigned an average broker rating score of 2.00 (Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating.
Brokerages have set a 1-year consensus price objective of $25.00 for the company and are predicting that the company will post $0.09 EPS for the current quarter, according to Zacks. Zacks has also assigned Simulations Plus an industry rank of 99 out of 256 based on the ratings given to related companies.
A number of brokerages have issued reports on SLP. Zacks Investment Research downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. BidaskClub downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, ValuEngine downgraded Zebra Technologies from a “buy” rating to a “hold” rating in a research note on Friday.
Several hedge funds and other institutional investors have recently modified their holdings of SLP. Rhumbline Advisers lifted its holdings in Simulations Plus by 48.5% during the 4th quarter. Rhumbline Advisers now owns 15,309 shares of the technology company’s stock worth $305,000 after purchasing an additional 5,000 shares in the last quarter. Royce & Associates LP raised its holdings in shares of Simulations Plus by 6,319.2% in the 4th quarter. Royce & Associates LP now owns 50,712 shares of the technology company’s stock valued at $1,009,000 after acquiring an additional 49,922 shares in the last quarter. Advisor Group Inc. raised its holdings in shares of Simulations Plus by 156.9% in the 4th quarter. Advisor Group Inc. now owns 2,112 shares of the technology company’s stock valued at $42,000 after acquiring an additional 1,290 shares in the last quarter. Martingale Asset Management L P raised its holdings in shares of Simulations Plus by 4.7% in the 4th quarter. Martingale Asset Management L P now owns 73,608 shares of the technology company’s stock valued at $1,465,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Bessemer Group Inc. raised its holdings in shares of Simulations Plus by 8.6% in the 4th quarter. Bessemer Group Inc. now owns 31,700 shares of the technology company’s stock valued at $631,000 after acquiring an additional 2,500 shares in the last quarter. 41.28% of the stock is currently owned by hedge funds and other institutional investors.
Simulations Plus stock traded up $0.50 during trading on Friday, hitting $31.74. 5,308 shares of the company were exchanged, compared to its average volume of 91,568. The firm has a 50 day simple moving average of $27.05. Simulations Plus has a 52 week low of $16.70 and a 52 week high of $32.42. The company has a market capitalization of $514.25 million, a P/E ratio of 63.60 and a beta of -0.38.
Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Wednesday, July 10th. The technology company reported $0.16 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.02. Simulations Plus had a return on equity of 24.08% and a net margin of 24.09%. The business had revenue of $9.94 million during the quarter, compared to the consensus estimate of $9.85 million. On average, research analysts predict that Simulations Plus will post 0.44 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Thursday, July 25th will be paid a $0.06 dividend. The ex-dividend date of this dividend is Wednesday, July 24th. This represents a $0.24 dividend on an annualized basis and a yield of 0.76%. Simulations Plus’s dividend payout ratio (DPR) is presently 48.00%.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Featured Story: What is Liquidity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.